Suda Pharmaceuticals Ltd. announce the appointment of Dr. Anil K. Sood to its Scientific Advisory Board. SUDA continues to progress with the development of its oral spray formulation of anagrelide to be used as an adjunct therapy for patients with thrombocytosis (elevated platelets) and metastatic disease. Dr. Anil K. Sood is Professor and Vice Chair for Translational Research in the Departments of Gynecologic Oncology and Cancer Biology and co-director of the Center for RNA Interference and Non-Coding RNA at The University of Texas MD Anderson Cancer Center.